Crinetics Pharmaceuticals (CRNX) recently submitted a Marketing Authorization Application to Brazil’s ANVISA for PALSONIFY, supported by data from 18 clinical trials, including two Phase 3 studies that met all primary and secondary endpoints.

The Brazil filing arrives after a strong run in recent days, with a 7 day share price return of 10.01% partly offsetting a weaker year to date share price return of 19.32% and contrasting with a 1 year total shareholder return of 42.91%.

If PALSONIFY’s progress has you looking at other healthcare names using AI, it could be worth scanning 37 healthcare AI stocks.

Crinetics now trades at US$37.70 with an intrinsic value estimate suggesting a wide gap. The stock is up 135% over 3 years, raising the question of whether there is still a buying opportunity or if future growth is already priced in.

Most Popular Narrative: 54.3% Undervalued

Crinetics closed at $37.70 while the most followed narrative points to a fair value around $82.43, creating a wide valuation gap for investors to assess.

The shift in acromegaly care toward patient friendly oral therapies, combined with PALSONIFY’s positioning as a potential first medical treatment after surgery, can expand treated patient numbers across switch, naive, previously discontinued and lost to follow up groups, which would directly influence revenue growth.

Want to see what could justify such a big difference between price and fair value? The narrative leans on rapid revenue expansion, margin change and a future earnings multiple that usually belongs to mature large caps, not a loss making biotech.

Result: Fair Value of $82.43 (UNDERVALUED)

However, this depends on PALSONIFY’s early launch translating into meaningful prescriptions, as well as on the broader pipeline avoiding further delays or clinical setbacks.

Another Angle on Valuation

Those big fair value gaps rely heavily on future cash flows, but the current pricing tells a different story. Crinetics trades on a P/B of 4x compared with 2.3x for the broader US Pharmaceuticals group and 9.3x for closer peers. This means you are already paying up for book value and need to be comfortable with that valuation risk.

To see how that stacks up in more detail, it is worth looking at how the numbers line up in a simple ratio breakdown, not just a complex model, and testing whether that premium feels justified for you personally See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly split between opportunity and risk, now is the time to look through the details yourself and decide what stands out. To weigh both sides quickly and form your own view, start with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you are weighing what to do next after reviewing Crinetics, take a few minutes to scan other ideas that might better fit your risk and return preferences.

• Target reliable cash flows by reviewing companies in the solid balance sheet and fundamentals stocks screener (40 results) that may support steadier business performance over time.
• Hunt for potential value by checking stocks in the 62 high quality undervalued stocks that combine quality fundamentals with pricing that could look attractive.
• Strengthen your income portfolio by scanning the 13 dividend fortresses and seeing which higher yielding names match your comfort with risk and payout stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.